These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2007-004539-44 SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY ... not-yet-due
Ongoing 2007-005517-20 Receptor radionuclide therapy with [177Lu- DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. not-yet-due
Completed, but no date Terminated 2008-002838-30 Phase II, randomized, multicentric study of docetaxel and zoledronic acid versus zoledronic acid in patient with prostate cancer and bone metastase treated with LHRH bad-data
Completed, but no date Terminated 2008-006366-29 IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY bad-data
Ongoing 2008-006525-14 CISPLATIN AND DOCETAXEL FOLLOWED BY SHORT-COURSE OF RADIOTHERAPY AND CONSOLIDATION CHEMOTHERAPY WITH CIPLATIN AND DOCETAXEL IN INOPERABLE NON SMALL CELL LUNG CANCER (NSCLC-STAGE III). not-yet-due
Ongoing 2009-014662-26 Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients. not-yet-due
Ongoing 2010-018333-21 Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line not-yet-due
Not reported Terminated 2010-019841-25 A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients 2014-07-15 due-trials
Ongoing 2010-020189-37 A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer not-yet-due
Ongoing 2010-020379-22 Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer. not-yet-due
Ongoing 2010-020772-38 A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breas... not-yet-due
Ongoing 2010-021248-16 ANGIOGENESIS IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS) IN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH BEVACIZUMAB not-yet-due
Ongoing 2011-002891-18 Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study. not-yet-due
Ongoing 2012-001410-41 Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic m... not-yet-due
Ongoing 2012-001786-32 Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic resp... not-yet-due
Completed, but no date Terminated 2012-003510-13 A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-p... bad-data
Ongoing 2012-003544-68 Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study. not-yet-due
Completed, but no date Terminated 2013-003150-25 Phase II Trial of Temozolomide in Patients affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer with MGMT methylation. GOPAV03 bad-data
Ongoing 2014-002602-20 CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CAN... not-yet-due
Completed, but no date Terminated 2014-003418-10 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS bad-data
Ongoing 2014-005095-28 Olaparib as salvage treatment for cisplatin-resistant germ cell tumor. not-yet-due
Ongoing 2014-005123-27 Complementary vaccination with dendritic cells pulsed with autologous tumor lysate in resected stage III and IV melanoma patients: a phase II randomized trial (ACDC adjuvant Trial) not-yet-due
Ongoing 2015-000556-14 Vaccination with dendritic cells pulsed with autologous tumor homogenate in combination with HD-IL2 and immunomodulating radiotherapy in metastatic RCC: a phase II trial (RENALVax-2) not-yet-due
Ongoing 2015-000894-11 Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study not-yet-due
Completed, but no date Terminated 2015-002419-14 Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PREV s... bad-data
Ongoing 2016-000767-17 A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study) not-yet-due
Ongoing 2016-004107-31 Randomized clinical trial of concomitant chemoendocrine therapy versus chemotherapy followed by endocrine therapy as first line treatment of luminal B metastatic breast cancer. not-yet-due
Ongoing 2016-004376-21 Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumors not-yet-due
Ongoing 2016-004452-29 Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) not-yet-due